Background: Temozolomide (TMZ) is the first-line chemotherapeutic drug for gliomas treatment. However, the clinical efficacy of TMZ in glioma patients was very limited. Therefore, it is urgently needed to discover a novel approach to increase the sensitivity of glioma cells to TMZ.
View Article and Find Full Text PDFShanghai Kou Qiang Yi Xue
February 2024
Zhongguo Ying Yong Sheng Li Xue Za Zhi
September 2022
Shanghai Kou Qiang Yi Xue
August 2021
Zhongguo Zhong Xi Yi Jie He Za Zhi
September 2015